The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom
| Autor: | Peter William Collins, Elizabeth Chalmers, M Richards, B. Palmer, Mary Mathias, Jayanthi Alamelu, Andrew M. Will, Charles R. M. Hay |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Adolescent Genotype Haemophilia A Population 030204 cardiovascular system & hematology Hemophilia A Haemophilia 03 medical and health sciences 0302 clinical medicine Interquartile range Internal medicine medicine Moroctocog alfa Humans Family history Child education Genetics (clinical) education.field_of_study Factor VIII business.industry Incidence (epidemiology) Immunogenicity Infant Hematology General Medicine medicine.disease United Kingdom Child Preschool 030220 oncology & carcinogenesis Female business |
| Zdroj: | Haemophilia. 24:896-901 |
| ISSN: | 1351-8216 |
| DOI: | 10.1111/hae.13551 |
| Popis: | Introduction\ud \ud Factor VIII inhibitor development is currently the most serious complication of the treatment of haemophilia A. Differences in manufacturing and the molecular structure of brands of recombinant factor VIII have led to speculation that concentrates may differ in immunogenicity. This has led to a regulatory focus on the immunogenicity of factor VIII concentrates both before and after licensure.\ud \ud \ud Aim\ud \ud To investigate the immunogenicity of ReFacto AF post licensure in a real‐world setting in previously untreated patients (PUPs) treated exclusively with this product until at least 50 exposure days (EDs).\ud \ud \ud Methods\ud \ud The United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) National Haemophilia Database (NHD) identified a consecutive cohort of patients with severe haemophilia A ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |